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Abstract: Embryonal tumors include a heterogeneous group of highly malignant 
neoplasms that primarily affect infants and children and are characterized by a high rate of 
mortality and treatment-related morbidity, hence improved therapies are clearly needed.  
G-quadruplexes are special secondary structures adopted in guanine (G)-rich DNA 
sequences that are often present in biologically important regions, e.g. at the end of 
telomeres and in the regulatory regions of oncogenes such as MYC. Owing to the 
significant roles that both telomeres and MYC play in cancer cell biology, G-quadruplexes 
have been viewed as emerging therapeutic targets in oncology and as tools for novel 
anticancer drug design. Several compounds that target these structures have shown 
promising anticancer activity in tumor xenograft models and some of them have entered 
Phase II clinical trials. In this review we examine approaches to DNA targeted cancer 
therapy, summarize the recent developments of G-quadruplex ligands as anticancer drugs 
and speculate on the future direction of such structures as a potential novel therapeutic 
strategy for embryonal tumors of the nervous system. 
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1. Introduction 
Embryonal tumors most commonly occur in the first few years of life and account for more than 
25% of childhood malignancies [1]. They include medulloblastoma (MB), neroblastoma (NB),  
soft tissue sarcomas, nephroblastoma (Wilm’s tumor), bone tumors, retinoblastoma, hepatoblastoma, 
germ-cell tumors and various other rare subtypes. This broad group of childhood tumors differs 
fundamentally from adult onset cancers, both in their cell biology and their tissue environment. 
Embryonal tumors originate from immature tissue as a result of the aberrant proliferation of early 
precursor cells and their morphological appearance resembles that of tissues in the developing embryo 
and fetus [2,3]. Most embryonal tumors are unfavorable malignant tumors with a relatively high 
proportion of children dying due to current therapy resistant disease. It is therefore likely that 
improved treatments for these cancers will only be possible when the molecular events that are specific 
to the tumors are better understood. 
MB and NB are malignant embryonal tumors of the central and peripheral nervous systems, 
respectively [4,5]. Childhood MB is a cancer of the cerebellum, while NB arises in the sympathetic 
nervous system showing heterogeneous biological and clinical features. Both MB and NB belong to 
the most challenging oncologic diseases of childhood that often show poor clinical prognosis. Despite 
intensive multimodal therapy, including surgery, chemotherapy and radiation, both high-risk NB and 
metastatic MB frequently acquire therapy resistance with fatal clinical outcomes. Moreover, many of 
the survivors suffer the risk of severe consequences from the intensive treatment; in particular children 
with MB who often experience long-term side effects mainly due to radiation therapy to the 
developing brain with high risks of severe morbidity even if cured of the tumor. Hence the 
development of novel therapeutic approaches based on identification of specific targets seems the most 
promising way forward to a better outcome for children with these unfavorable malignant tumors [6,7]. 
Anticancer agents that target DNA are some of the most effective agents in clinical use and have 
produced significant increases in the survival of cancer patients but, unfortunately, they are extremely 
toxic. Consequently, much effort has been put into finding agents that are more selective and there is 
considerable excitement that the identification of cancer-specific DNA targets will yield a new 
generation of less toxic therapeutics [8]. Secondary DNA structures, such as G-quadruplex nucleic 
acids, have recently emerged as a new class of molecular targets for DNA-interactive compounds. 
These elements are nonclassical four-stranded secondary structures arising from the folding of a single 
DNA strand that comprises stretches of tandem guanines. G-quadruplexes are found to be present in 
biologically important regions of DNA that are essential for cancer cells to proliferate indefinitely such 
as telomere and regulatory regions of oncogenes. Owing to the abundance of detailed information 
available regarding their thermodynamic stabilities [9] and their potential anticancer activities,  
G-quadruplexes are viewed as emerging therapeutic targets in oncology [10–14]. Several compounds 
that target these structures have shown promising anticancer activity in tumor xenograft models and 
some of them have entered Phase II clinical trials. This review examines approaches to DNA targeted 
therapy, describes recent developments of G-quadruplex ligands as anticancer drugs and discusses 
their potential as therapeutic targets, for embryonal tumors of the nervous system. 
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2. DNA as a Target for Anticancer Therapy 
DNA has played a role as a successful molecular target for many of the drugs that have been used 
for decades in cancer therapeutics and there are good reasons to expect DNA will continue to be a 
clinically important target for many years to come [8]. Anticancer chemotherapies that target DNA are 
some of the most effective drugs in the clinical use and have produced significant increases in the 
survival of pediatric cancer patients [15]. Most of these chemotherapeutic are DNA-damaging agents 
that have been proven to cause relative potent destruction of tumor cells. However, the clinical 
potential of DNA-damaging agents is undermined by the adverse side effects and increased risk of 
secondary cancers that are consequences of the agents' genotoxicity [16]. 
DNA integrity is critical for proper cellular function and proliferation. DNA damage is detected by 
cell-cycle checkpoint proteins, whose activation induces cell-cycle arrest to prevent the transmission of 
damaged DNA during mitosis. If damaged DNA cannot be properly repaired cell death usually results [17]. 
The rationale for targeting DNA to treat cancer is based on the facts that rapidly proliferating tumor 
cells depend upon DNA integrity more than normal quiescent cells [16]. 
DNA-damaging compounds with anticanceractivity were shown to target DNA either directly or 
through inhibition of enzymes that control DNA integrity or provide building blocks for DNA. There 
are several established therapeutic modalities targeting DNA: (i) antimetabolites which are DNA 
antagonists that exert their activity by blocking nucleotide metabolism pathways, such as capecitabine, 
floxuridine, and gemcitabin as well as the canonical folic acid antagonists such as methotrexate;  
(ii) alkylation agents that cause direct DNA damage. These include compounds that directly modify 
DNA bases, intercalate between bases, or form cross-links in DNA, such as nitrogen mustards and 
their derivatives that directly alkylate DNA on purine bases, leading to stalled replication fork 
progression and subsequent cell death via apoptosis. Other DNA alkylators which are currently used in 
clinical therapeutics include cyclophosphamide, chlorambucil, melphalan, carmustine, lomustine, 
semustine, dacarbazine and temozolomide [8]. Temozolomide is a monoalkylation drug which 
methylates guanine residues in DNA. The most potent and efficacious agents, however such as 
chlorambucil and melphalan, were found to crosslink the two complementary strands of DNA, rather 
than just alkylating one strand. Intercalators such as actinomycins bind DNA and inhibit the activity of 
many enzymes that use DNA as a substrate; (iii) in addition to alkylating agents antitumor antibiotics 
such as doxorubicin, bleomycin and distamycin have made an important impact on the treatment of 
cancer patients; (iv) among the most widely and successfully used anticancer agents today are 
nonspecific DNA-damaging chemicals, including inhibitors of topoisomerases (TOPO) I and II and 
agents causing covalent modification of DNA such as mitomycin C, streptozotocin and platinum 
compounds [16]. Natural products which alkylate DNA bases such as mitomycin C and streptozotocin 
crosslink DNA on opposite strands of the double helix, resulting in a more potent effect against cancer 
cells compared to monofunctional alkylation. The discovery of the alkylating agent-like platinum 
agents such as cisplatin had a significant positive impact on anticancer drug research. Indeed, cisplatin 
therapy can cure over 90% of all testicular cancer cases and also has good efficacy in the treatment of 
ovarian, bladder, head and neck, and cervical cancers [17,18]. DNA remains a promising target for 
anticancer drug development, but DNA damage to normal cells as well is not a prerequisite for  
anti-tumor activity. The focus until recently was on double-stranded (ds) DNA structures that have been 
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known for 60 years [19]. Chemotherapeutical drugs that are currently used in cancer therapy are 
thought to act through the unspecific recognition of highly ‘active’ ds DNA in cancer cells that is in 
replication at high frequency and therefore relatively exposed to recognition by DNA targeting 
molecules. Following DNA recognition by these compounds, the subsequent interaction involves 
either intercalation of the ligand’s planar aromatic rings between two adjacent DNA base pairs, or 
major or minor-groove binding (Table 1). However, nonspecific binding through electrostatic 
interactions with the negatively charged sugar-phosphate backbone frequently occurs. Consequently, 
this has driven interest in the targeting of unusual, non-canonical structures in DNA, in order to 
achieve selectivity while potentially reducing adverse side effects [20]. One DNA structure that has 
attracted significant attention as an anticancer target is the G-quadruplex [16]. Compared to duplex 
DNA, G-quadruplexes have much more compact structures that contain well-defined binding sites for 
small molecules. It has been proposed that the different structural morphology of G-quadruplex DNA, 
will provide different G-quadruplex recognition site for binding different G-quadruplex interacting 
ligands. Small organic molecules have been proposed to interact noncovalently with G-quadruplex 
through stacking on the ends of the G-tetrad core, groove binding, taking the place of one or more 
strands in the core, interacting with the backbone (core and loops), or interacting with the loop bases 
These G-quadruplex elements are often present in biologically important regions of DNA that greatly 
required by cancer cell to proliferate untimely such as telomere and regulatory regions of oncogenes 
such as MYC. Thanks to the abundance of detailed information available regarding their potential 
biological activities, G-quadruplexes are viewed as emerging therapeutic targets in oncology [10–14]. 
Table 1. Interaction patterns between drug/small molecules and double stranded DNA. 
Drug 
Mode of Binding 
Covalent Non covalent 
Alkylating agents (irreversible 
and leads to complete inhibition 
of DNA processes and 
subsequent cell death) 
Groove binders 
Intercalators 
Minor 
groove 
binders 
Major 
groove 
binders 
Cisplatin  
(DNA crosslinker) 
√     
Doxorubicin  
(Stabilizes topoisomerase-II–DNA 
cleavable) 
√    
Etoposide  
(Topoisomerase inhibitor) 
√    
Methotrexate  
(Antimetabolite, a folic acid antagonist) 
√    
(TFOs) Triplex-forming oligonucleotides 
(oligomers that bind in the major groove 
and form hydrogen bond with bases of the 
purine strand) 
  √  
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Table 1. Cont. 
Drug 
Mode of Binding 
Covalent Non covalent 
Alkylating agents (irreversible 
and leads to complete inhibition 
of DNA processes and 
subsequent cell death) 
Groove binders 
Intercalator
s 
Minor 
groove 
binders 
Major 
groove 
binders 
(PNAs) peptide nucleic acids  
(with peptide-like backbone that invade the  
helix to form a triplex which results in the  
displacement of noncomplementary 
oligopyrimidine DNA strand) 
  √  
(Daunomycin) combilexins    √ 
Quinacrine    √ 
Ethidium bromide    √ 
Netropsin  √   
Distamycin  √   
DAPI  √   
3. G-Quadruplexes 
Guanine (G) -rich DNA sequences are susceptible to form in vitro G-quadruplexes as a 
consequence of the propensity of guanines to associate with each other in a stable hydrogen-bonded 
arrangement, the G-quartet [21–23]. G-quartets are stabilized by a monovalent cation (Na+ or K+) 
localized in the centre of the structure. Both nuclear magnetic resonance and X-ray crystallographic 
structures of G-quadruplexes have been obtained at high resolution [24,25]. Variations in the 
molecularity, topology, strand orientation and glycosidic conformation of the G-quadruplex DNA 
provide a diverse array of structures [26]. A three-dimensional arrangement of three G-quartets can 
result in a variety of G-quadruplex structures. The four-stranded quadruplex structural types depend on 
the number and the orientation of the DNA strands. Indeed, intramolecular G-quadruplexes are 
comprised of one DNA strand whereas dimeric and tetrameric intermolecular quadruplex involve two 
and four DNA strands, respectively. G-quadruplex heterogeneity also depends on the orientation of the 
DNA strands (parallel or anti-parallel) and the guanine conformation (syn or anti) [24,27,28]. Despite 
a wealth of crystal and solution structures, it has proved difficult to define a comprehensive set of rules 
that specify the folding propensity of G-quadruplexes based on specific sequences, moreover it has 
been reported that the same sequence can adopt different G-quadruplex conformations [29].  
There is extensive literature on proteins that have been identified to bind G-quadruplexes [30–32], 
including proteins that either facilitate or non-catalytically disrupt G-quadruplex formation, as well as 
helicases that catalytically unwind G-quadruplexes in an ATP-dependent manner and nucleases that 
cleave at G-quadruplex scaffolds [33]. Although G-quadruplex structures have only been observed in vitro, 
strong indirect evidence for their existence in vivo comes from the characterization of G-quadruplex 
DNA binding proteins, helicases, and nucleases. [26,34]. Moreover monoclonal antibodies have been 
used successfully to confirm their in vivo, existence [35] however, controversial reports exist [36,37]. 
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Bioinformatics and molecular sequence analysis indicates that G-quadruplexes are over-represented in 
specific regions of the genome with key biological contexts. This includes DNA telomere ends and 
promoter regions (translation start sites) of several important oncogenes [21,33,38,39]. It has been shown 
that the formation of quadruplexes inhibits the telomere extension by the telomerase enzyme, which is 
up-regulated in cancer cells, as well as negatively regulating oncogene’s transcription [40,41] Because 
of its biological significance and antitumor potential, the G-quadruplex has attracted intense interest as an 
important target for drug design and development and there is a huge interest in design and development of 
small molecules to target these structures. A large number of so-called G-quadruplex ligands, displaying 
varying degrees of affinity and more importantly selectivity, have been reported [42,43]. 
RNA structures in the untranslated regions (UTRs) of mRNAs influence post-transcriptional 
regulation of gene expression. There is now a growing body of evidence that has established a link 
between deregulation of translational control and disruption of normal cell behavior in human diseases, 
especially cancers. While much of the research has been focused on DNA G-quadruplexes, there has 
recently been a rapid emergence of interest in RNA G-quadruplexes, particularly in the 5′-UTRs of 
mRNAs. The recent in vitro demonstrations that small molecule G-quadruplex binding ligands can 
selectively target RNA G-quadruplexes open up a new and attractive avenue in RNA-directed drug 
design. Clearly, part of the challenge is to better understand the mechanistic effects and selectivity  
in vivo environment, however, it is clear that the RNA G-quadruplex motif represents a structurally 
attractive scaffold for small molecule targeting and given the promising early insights into their 
functional effects, this represents an attractive and fertile area for future research [10,33]. 
4. G-Quadruplexes as a Potential Cancer Therapeutic Targets 
4.1. Telomere Structure and Function 
The concept of targeting G-quadreplexes as a therapeutic strategy was first developed for telomeric 
DNA and telomerase inhibition. Telomeres are specialized DNA–protein complexes that cap the ends 
of linear chromosomes and provide protection against gene erosion at cell divisions, chromosomal 
nonhomologous end-joinings and nuclease attacks [44–46]. Telomere DNA consists of repetitive 
TTAGGG double-stranded tracks that span ~10–15 Kb in length in humans and terminate with around 
200-nt of a G-rich single-stranded overhang beyond the double-stranded region [47,48]. The single 
stranded DNA folds back and anneals with the double-stranded region to form a large telomeric loop, 
known as the T-loop [49]. As a consequence, a portion of the strand along the length of the  
overhang-invasion is displaced, forming a single-strand DNA region called a D-loop [50]. A group of 
telomere-associated proteins which help to stabilize the T-loop secondary structure are collectively 
called shelterins. These shelterin proteins comprise the telomere repeat factor 1 and factor 2 complexes 
(TRF1 and TRF2) that bind to double-stranded telomeric DNA and the protection of telomeres 1 protein 
(POT1) that binds the single-stranded 3` G-rich overhang. Three other interconnecting proteins (TIN2, 
TPP1, and RAP1) protect the telomere integrity by assisting in the T- and D-loop formation [51,52]. 
Telomere DNA in human cells shortens during each round of chromosome replication due to the  
end-replication problem [53,54]. In more than 85% of cancer cells, the telomere shortening is 
compensated by the telomerase enzyme that is especially up-regulated in cancer but not in somatic cells. 
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Telomerase is a cellular ribonucleoprotein enzyme that stabilizes telomere length by adding 
TTAGGG repeats to the telomeric ends of the chromosomes. Human telomerase is composed of two 
main components, human telomerase RNA (hTR) and telomerase reverse transcriptase TERT [55–58]. 
This enzyme utilizes its own RNA as a template to synthesize telomeric DNA. Together with 
telomere-binding proteins, telomerase confers stability on the chromosomes and counteracts the 
telomere-dependent pathways of cell mortality. Telomerase activity changes through life, going from a 
peak of activity during the first trimester in utero, where virtually all the tissues have active  
telomerase [59], to undetectable levels after birth in most somatic tissues with the exception of highly 
proliferative cells such as germ cells and stem cell compartments [60]. Beside telomerase, in some 
tumors, telomeres are maintained by an alternative lengthening of telomere (ALT) mechanism [61–63].  
In this process telomeres are usually longer and more heterogeneous than in telomerase-positive cells. 
However, the exact mechanisms involved in telomere elongation are poorly understood. 
4.2. Biological Significance of Telomeres and Telomerase during Development 
Highly proliferative cell types such as embryonic cells require active and controlled telomere 
maintenance strategies in order to protect the integrity of their genomes effectively. Telomere length 
was found to be regulated during human and animal embryogenesis by a telomerase-dependent 
mechanism [64]. In germ line cells, human telomeres are balanced between shortening processes with 
each cell division and elongation by telomerase, but once the cell is terminally differentiated or 
mature, the equilibrium is shifted to gradual telomere shortening by repression of the telomerase 
enzyme [65–71]. Embryonic stem cells that are capable of self-renewal and differentiate to any cell type 
in the body, maintain high levels of telomerase activity and TERT expression [72–75]. In 20 week old 
human foetus after the embryonic period and most of the organogenesis is accomplished, telomerase is 
rapidly down-regulated and expressed only at lower levels in tissue-specific stem cells [76,77]. 
4.3. Telomeres and Telomerase Activity during Tumor Development 
Despite the impressive advances that have been made in cell and molecular biology, how embryonal 
tumor cells are actually initiated and progress is still widely debated. The concept that the incidence of 
cancer rises exponentially in the final decades of life due to the sequential accumulation of the somatic 
mutations does not really fit the onset of pediatric cancers that develop and manifest early in 
childhood. Identification of the cells that mediate tumor initiation in childhood cancer and finding out 
the information that is necessary for the cell to transform into a neoplastic cell should provide an 
important baseline for better treatment of childhood embryonic cancers [78,79]. 
Different hypotheses have been postulated in the literature: one assumes that a somatic 
differentiated cell can dedifferentiate or reprogramme to regain properties associated with cancer cells 
whereas others claim that a stem cell is needed to initiate the carcinogenic process [80]. The first 
model scenario depends on the hypothesis that rapid proliferation of the telomerase negative 
dedifferentiated somatic cells can lead to shortened telomeres that may promote chromosomal and 
genomic instability which then primes the cell to become cancerous. In a later stage telomerase is then 
activated and stabilizes the previously shortened telomeres, thereby prolonging the lifespan of cancer 
cells. This hypothesis has been supported experimentally by the observation that almost all malignant 
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cancers have telomerase activity, despite their shortened telomeres [65,81–84]. Indirect support for this 
view comes from the observations that benign or pre-cancerous lesions are telomerase silent [81]. 
Moreover high telomerase levels are found to correlate with worse clinical outcomes [85]. This model 
implies that telomerase activation in cancer is an induced or aberrant function in otherwise  
enzyme-deficient somatic cells destined for senescence [86]. The second interesting hypothesis is that 
the tumor cells are telomerase positive not because of TERT expression under a selective pressure, but 
because they are derived from the oncogenic transformation of a stem cell or a pluripotent early 
precursor cell which has retained its telomerase activity [76,86,87]. This concept has been proposed 
for several tumors [88] and supported by a number of reports demonstrating the presence of cancer 
stem cells in different adult cancers [89,90]. In pediatric malignancies the cancer stem cell hypothesis 
was recently described in studies performed on leukaemia, where it was shown that a single cell with 
stem cell markers had the capability to induce the disease in mice [91]. More recently, cancer stem 
cells have also been isolated from solid embryonal tumors such as MB, NB, Ewing’s sarcoma, RMS 
and HB [92–97]. The second model scenario highlights the importance of telomere length maintenance 
in stem cell populations to facilitate cell division that is required for tissue homeostasis. However there 
has to be a balance between maintaining regenerative potential, on one hand and tumor suppression on 
the other. One mechanism that may contribute to adjust this balance is the length of telomeres per se, 
whereby stem cells may need to maintain telomeres at a length that provides sufficient replicative 
capacity for tissue homeostasis, versus the requirement to minimize telomere length and replicative 
capacity as a tumor suppressive mechanism [98]. There is a suggestion that during the tumorigenesis 
process telomere erosion may have evolved to a level where telomeric repeat sequences are too short 
to provide a functional substrate for telomerase enzyme activity [99]. In this scenario, as telomeres 
shorten with each cell cycle the “sticky” ends of chromosomes become prone to fusions [100] leading 
to subsequent chromosomal instability [100–103] and offering a mechanism for a continuous 
rearrangement of chromosome structure that might contribute to oncogene amplification and tumor 
suppressor gene deletion [104,105]. In fact, concurrent telomere shortening and genomic instability 
have been observed in the majority of embryonic tumors including: Wilms’ tumor [106,107],  
MB [108,109], NB [110,111] and rhabdomyosarcoma [112,113]. The view represented by the stem 
cell origin of embryonal tumors implies that the genetic alterations which lead to cancer accumulate in 
embryonal stem cells rather than mature cells. However, an alternative opinion held is that it is 
important to separate tumor-initiation and tumor-propagation; this may not involve the same cell type 
as the tumor-propagating cell may be a much differentiated progeny of the tumor-initiating cell. Hence 
improved therapeutic efficacy may be achieved by targeting both cell types which drives malignant 
progression as well as thesewhich initiates and maintains the stem cell pool of the tumor [114]. 
Ultimately whether embryonal cancer cells reactivate the telomerase or up-regulated telomerase 
activity, the telomere maintenance process seems to play a crucial role in the initiation and progression 
of cancer. Since telomerase is not expressed in most normal human cells, this has led to the 
development of targeted telomerase cancer therapeutic approaches which are at present in advanced 
clinical trials. 
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4.4. Significance of Telomere Biology in Embryonal Tumors of the Nervous System 
The erratic clinical behaviour of pediatric embryonal tumors suggests a variable proliferative potential, 
thus making them attractive candidates for the study of telomere maintenance biology as a possible 
prognostic marker and/or therapeutic target. Elevated telomerase activity and telomere shortening 
could be signs of the excessive cell divisions experienced by cancer cells and could reflect the stage of 
malignancy and disease prognosis [115]. Down-regulation of telomerase activity has been shown to 
induce cancer cell growth arrest and differentiation, which might predict a close correlation between 
telomerase activity levels and clinical outcome, while tumors with sustained telomerase activity might 
therefore become choice targets for telomerase directed therapy [116–119]. Telomere maintenance biology 
have been studied in the majority of embryonic tumors including Wilms’ tumor [106,107,120],  
Ewing’s sarcoma [121–123], hepatoblastoma [8,124], MB [108,109,125,126], NB [127,128] and 
rhabdomyosarcoma [112,129]. We will focus below on pediatric malignancies of the central and 
peripheral nervous system MB and NB. 
4.4.1. Neuroblastoma 
NB is the most common extra-cranial solid tumour of childhood and accounts for at least 15% of 
cancer-related deaths in children [4]. NB is derived from primitive cells of the sympathetic nervous 
system and so it can be found anywhere along the paravertebral sympathetic chain or in the adrenal 
gland [130,131]. The clinical outcome of NB can range from complete regression (mainly in infants) 
to rapid tumor progression and metastasis with poor prognosis [132]. Identification of the most 
common genomic alterations associated with the disease has allowed the classification of NB into  
low-, intermediate- and high-risk groups [4,133]. Unfavorable tumors are characterized by deletions of 
1p or 11q, unbalanced gain of 17q and/or amplification of MYCN [134]. 
Studies by several independent laboratories aimed at understanding the dynamics of  
telomere-telomerase interaction in NB suggested that telomerase activity is a robust prognostic 
indicators [127,128,135–137] and can discriminate between prognostically different subsets of  
NB [85,138,139]. Hiyama et al. reported that telomerase is expressed in 94% of NB patients’ samples, 
but not in benign ganglioneuromas or adjacent adrenal tissues: 75% of tumors with high telomerase 
activity had a poor prognosis, 97% of tumors with low telomerase activity had a good prognosis and 
100% of tumors with no detectable telomerase activity regressed [85,135]. Similarly, in a study of a 
large cohort, telomerase activity was detected in 39/133 (29%) tumors including 25/41 (61%) Stage 4, 
8/23 (35%) Stage 3, 0/13 (0%) Stage 2, 2/32 (6%) Stage 1 and 4/24 (17%) Stage 4S NB. In this study 
telomerase activity emerged as an independent predictor of clinical outcome with greater prognostic 
impact than the MYCN status and even the clinical stage [140]. The level of RNA subunit of 
telomerase (hTR) has also been found to be associated with the clinical stage of NB at diagnosis [141]. 
High expression of hTR was associated with advanced disease and with unfavorable prognosis, while 
most patients with weak or absent hTR expression were found to belong to early tumor stages [138,141]. 
NB patients classified as 4S stage, known to have a good prognosis and usually demonstrating 
spontaneous regression, were found to exhibit short telomeres and to express no detectable telomerase 
activity at diagnosis, in contrast to patients with progressive disease [135,136]. Hence it has been 
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hypothesized that the aggressive tumors express telomerase (and therefore have stabilized telomeres), 
whereas the regressing tumors may have absent or low levels of telomerase activity (allowing telomeres 
to continue shortening). In a retrospective study on 124 NB, Krams et al. have shown that both spliced and 
full-length hTERT transcripts were significantly associated with MYCN amplification while full-length 
hTERT transcripts were highly predictive of poor outcome [142]. In a recent work we examined telomestatin, 
a G-quadruplex interactive agent, for its ability to inhibit telomere maintenance of neuroblastoma cells. 
In this study treatment with telomestatin resulted in telomerase inhibition, telomere shortening, cell 
growth suppression and induction of apoptosis through disruption of telomere maintenance [143]. 
4.4.2. Medulloblastoma 
MB is a malignant, invasive tumor of the cerebellum and the most common primary pediatric 
malignancy of the central nervous system. Classified as a primitive neural ectoderm tumor that is 
thought to arise from granule cell precursors. The standard of care consists of surgery, chemotherapy 
and age-dependent radiation therapy. Despite aggressive therapy approximately 30% of MB patients 
remain incurable. Moreover, for long-term survivors, the treatment related sequelae are often debilitating. 
Side effects include cerebellar mutism, sterility, neurocognitive deficits and a substantial risk of 
developing secondary cancers. Hence more effective and targeted therapies are certainly needed [144]. 
In contrast to NB, data on the role of telomere/telomerase biology in MB are scarce and 
examination of the few reports that do exist yields conflicting results. Studies have shown that large 
increases in chromosomal material in the 5p15 region, where the TERT gene is located, are detectable 
in MB, suggesting that the TERT gene could be amplified in CNS embryonal tumors [83,145,146]. 
Fan et al. used differential PCR and real-time RT-PCR to determine the relationship between TERT 
gene copy number, TERT mRNA expression and clinical outcome in CNS embryonal tumors 
including MB [147]. The group found that the TERT gene was amplified in 42% of 36 primary MB 
samples examined. The TERT amplification was found to correlate with the increased expression of 
TERT mRNA in almost all the tumors, while MB patients with increased TERT expression in their 
tumors showed a trend towards worse clinical outcomes. The authors suggested that changes may have 
happened at the TERT locus during the evolution of MB, indicating a possible role for telomerase in 
the pathogenesis of MB [147]. Other groups, including our laboratory [148–151], detected telomerase 
enzyme activity in cultured MB cells in vitro. Our lab investigated the mRNA expression level of 
TERT in 50 primary MB samples and compared it with seven normal brain samples. 76% of the 
primary MB samples had upregulated TERT mRNA expression [148–151]. While a positive 
correlation between TERT mRNA expression and telomerase activity was detected in MB cell lines, 
no correlation was found between telomerase activity and telomere length. Treatment of MB cell lines 
with the telomerase inhibitor epigallocatechin gallate displayed strong dose dependent proliferation 
inhibitory effects against telomere repeat amplification protocol (TRAP)-positive MB cell lines [148–151]. 
Our results suggest that inhibition of telomerase function could represent a novel experimental 
therapeutic strategy in childhood MB. In contrast, however, by screening a heterogeneous group of 
brain tumors for telomerase activity, MB was found to be the only telomerase negative in the series of 
brain tumors tested [152,153]. Hence these results may provide a stimulus for future research aimed at 
uncovering the real role, if any, that telomere maintenance might play in the pathogenesis of MB. 
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4.5. Significance of the myc Oncogene Family in Embryonal Tumors of the Nervous System 
4.5.1. MYC in neuroblastoma 
The myc family of nuclear oncogenes contains three well-characterized members, c-myc (MYC), 
MYCN, and L-myc. These genes encode related but distinct nuclear proteins that can contribute to 
tumorigenic conversion both in vitro and in vivo. However, each gene displays a unique activation 
pattern that partially reflects the distinctive expression of each gene during normal tissue as well as 
during tumor development [153]. MYCN amplification in NB has been established as a predictive 
marker for poor outcome which is associated with a survival rate of 15%–35% [154,155]. MYCN is 
vital for proliferation, migration and stem cell homeostasis while decreased levels are associated with 
terminal neuronal differentiation. In addition, high risk tumors without MYCN amplification frequently 
express elevated levels of MYC [156]. Recent microarray data from NB patients showed that genes in 
the MYC pathway significantly correlated to poor survival independent of MYCN amplification [157]. 
By using these expression profiles, the authors identified patients with adverse outcomes that initially 
were diagnosed as low or intermediate risk [157], emphasizing the importance of MYC signaling in 
NB biology. Retinoic acid has been shown to downregulate MYCN expression and to induce neuronal 
differentiation of NB cells in vitro. Together, these findings indicate that MYC signaling is important 
in maintaining an undifferentiated phenotype and that inhibition of MYC could contribute to less 
aggressive tumors and maybe even lead to new and improved therapies for high-risk patients 
(reviewed in [158]). Several labs have explored the effect of down regulating MYCN expression in 
MYCN-amplified NB cell lines using antisense or RNA interference approaches in vitro and  
in vivo [159–165]. Collectively these studies demonstrated that decreased MYCN expression in NB 
cells leads to growth arrest, apoptosis and/or differentiation. The results of these studies indicate that 
MYCN could be a promising therapeutic target for NB. However the use of antisense or RNA 
interference as a therapeutic strategy in the clinic has been limited due to insufficient delivery and 
specificity problems. It is therefore of particular relevance to find an alternative approach to achieve a 
better targeting of MYCN in NB in view of discovering new therapeutic targets.  
4.5.2. MYC in medulloblastoma 
MYC has emerged as an important modulator and prognostic indicator of MB malignancy [166–168]. 
Amplification of MYC has been reported in 5%–15% of MB overall, while amplification of MYCN has 
been found in ~10% of cases [169–171]. MYC expression and amplification have been associated with 
poor patient prognosis [166,172] and with the prognostically dismal large cell/anaplastic MB  
subtype [167,171,173]. MYCN was shown to be upregulated by Hh signaling and to mediate the 
effects of Hh activation on the proliferation of cerebellar granule precursors [174,175]. MYC was 
found to cooperate with Hh by enhancing tumorigenicity of nestin-expressing neural progenitors that are 
present in the cerebellum at birth and that can act as the cells-of-origin for MB [176] and reviewed in [177]. 
Based on the above, MYC appears to play a central role in deviating many of the signaling pathways 
to specific effectors involved in MB pathogenesis, therefore it represents an attractive target for the 
therapy of these neoplasms. However, contrary to the substantial amount of preclinical studies in NB, 
the investigation of MYC-specific therapeutic approaches in MB is still in its infancy. Unfortunately, 
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clinically useful inhibitors of MYC are not available to date and efforts to develop such drugs would 
certainly be needed. Our lab as well as others used an antisense approach to silence MYC [178], which 
led to an inhibition of cell proliferation and to an arrest of the cell cycle in the S phase. The synthetic 
quassinoid derivative NBT-272, is currently under investigation in our group, on the basis of previous 
findings obtained in a panel of MB-derived cell lines [179]. In this report, NBT-272 was able to reduce 
cell proliferation and to block cell cycle progression [180]. We evaluated recently the effects of  
G-quadruplex targeting compound S2T1-6OTD on a representative panel of human MB and atypical 
teratoid/rhabdoid AT/RT childhood brain cancer cell lines. S2T1-6OTD is a novel telomestatin 
derivative that is synthesized to target G-quadruplex-forming DNA sequences in the MYC promoter. 
We showed that treatment with S2T1-6OTD reduced the mRNA and protein expressions of MYC and 
hTERT, which is transcriptionally regulated by MYC, and decreased the activities of both genes. In 
remarkable contrast to control cells, short-term (72-hour) treatment with S2T1-6OTD resulted in a 
dose and time-dependent antiproliferative effect in all MB and AT/RT brain tumor cell lines tested 
with IC50 at micromolar level. Under conditions where inhibition of both proliferation and MYC 
activity was observed, S2T1-6OTD treatment decreased protein expression of the cell cycle activator 
cyclin-dependent kinase 2 and induced cell cycle arrest. Long-term treatment (5 weeks) with nontoxic 
concentrations of S2T1-6OTD resulted in a time-dependent (mainly MYC-dependent) telomere 
shortening. However, telomestatin is known to bind to the G-quadruplex in the TERT promoter, and 
this may mediate at least part of its effect on TERT [180]. Telomere shortening was accompanied by 
cell growth arrest and followed by cell senescence and induction of apoptosis in all five cell lines 
investigated [181,182]. Ref.181 missing In vivo animal testing will now be needed to determine 
whether S2T1-6OTD may represent a novel therapeutic strategy for childhood brain tumors. 
5. Targeting G-Quadruplex as a Novel Anticancer Strategy 
5.1. Targeting Telomere Maintenance 
The interest in telomere maintenance mechanisms in a cancer therapeutics context came to light 
following the observations that immortality of human cancer cells is intimately related to the 
maintenance of the ends of human chromosomes [183,184]; in addition over 85% of human tumor 
samples including cancer stem cells are telomerase-positive [56–58]. In fact no other tumor-associated 
gene is as widely expressed in cancer. This concept was coupled with the remarkable reports by Hahn 
and colleagues’ showing that cloning a mutant TERT gene into a cancer cell causes the cell to lose the 
ability to form tumors in mice, leads to shortening of telomeres and forces the cell into replicative 
senescence [183,185]. Soon afterwards cumulative reports continued to demonstrate and provide 
evidence for the genetic validation of telomere maintenance as an anticancer target [186–189]. 
Telomere DNA in human cells shortens during each round of chromosome replication due to the 
end-replication problem [53,54]. In most cancer cells the telomere shortening is compensated by the 
telomerase enzyme. Optimal telomerase activity requires the unfolding of the single-stranded 3' ends 
of telomeric DNA substrate that gives access to the telomerase RNA to allow priming and elongation 
of the telomere length. To this end, telomerase hybridize to the single-stranded 3′ ends of telomeric 
DNA and add new nucleotides in order to maintain telomere length and accordingly uphold the 
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proliferative ability of the cancer cells [81,190]. This link to cancer biology propelled the development 
of new strategies to limit cancer cell growth using the interference with telomere maintenance via 
telomerase inhibition [191,192]. One recent approach to telomerase inhibition involves the sequestration of 
the single-stranded 3′ ends of telomeric DNA into higher-order quadruplex structures [190,193]. A desired 
ligand would recognize a G-quadruplex structure formed by human telomeric sequences with high 
affinity and specificity. Many of the reported G-quadruplex ligands contain planar aromatic rings, 
which can interact with human telomeric G-quadruplex by stacking on the terminal G-tetrads (Figure 1). 
Figure 1. Interaction modes between G-Quadruplex structures and ligands. 
A C 
 
 
 
 
B
Ligand
G-quadruplex with 
three stacked 
quartets, linked by 
the DNA backbone
 
Small organic molecules have been proposed to interact noncovalently with G-quadruplex through (A) tetrad 
end stacking, (B) groove binding and (C) intercalation between the two G-tetrads. 
In addition to the end-stacking binding mode of the aromatic rings, some ligands also contain other 
moieties that can recognize loops by stacking with loop bases or forming intermolecular hydrogen 
bonds or recognize the backbone with electrostatic interactions. The grooves in G-quadruplexes can 
also be recognized through hydrogen bonds or hydrophobic interactions Alternatively the G-rich human 
telomeric DNA strand can be trapped in a G-quadruplex structure with a linear guanine-containing 
molecule based on a different backbone, such as PNA [194]. 
The formation of a quadruplex-ligand complex at telomere ends appears to be equivalent to the 
exposure of damaged DNA, since it elicits a rapid DNA damage response that is lethal to the affected 
cancer cells [195]. Several selective drug-like small molecule ligands were developed to target the 
quadruplex forming 3′-telomeric end DNA sequences and a growing number of different cancer 
research groups including our lab, started to use some of these compounds to test cancer growth 
inhibitory effects [196–198]. Most of the small molecules discovered showed a strong ability to 
stabilize these motifs and were successful in telomerase inhibition, thereby identifying the human 
telomeric DNA G-quadruplexes as attractive potential targets for cancer therapeutic intervention [8,187]. 
However lack of selectivity towards telomere quadruplex motifs has been also reported [187]. 
Interestingly some G-quadruplex-targeting compounds have been shown to disrupt telomere capping 
and induce rapid apoptosis in cancer cells, even in the absence of telomere shortening [186,187]. This 
finding cannot be explained solely by telomerase inhibition. Rather, it indicates to a certain extent that 
the direct target of these ligands is telomere dysfunction rather than telomerase inhibition. Furthermore, 
G-quadruplex-targeting compounds have also been shown to inhibit the alternative lengthening of 
telomeres (ALT) pathway, which maintains telomere stability in a telomerase-independent manner in 
around 15% of cancer cells whereby telomerase is not activated [199]. 
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5.2. Targeting G-quadruplexes in Oncogene Promoters 
In addition to their existence in telomere sequence, bioinformatic analyses combined with biophysical 
and structural investigations have highlighted the relative abundance of putative G-quadruplex forming 
sequences in promoter regions of oncogenes close to their transcription start sites [200,201]. 
Oncogenes with putative G-quadruplex forming sequences in their promoters includes: c-kit [202,203]; 
k-ras [204]; hTERT [205,206]; Bcl-2 [207]; VEGF [208]; HIF-1[209]; c-myb [210]; c-myc [211–213] 
PDGF-A [214] pRb [215] reviewed in [216]. Interestingly it has been shown that the potential for 
quadruplex formation is higher within oncogenes` promoters compared to tumor suppressor  
genes [199,217]. Considerable focus has been placed on the MYC gene promoter making it the most 
extensively studied system for the G-quadruplex formation [112,199,211,218,219] important regulator 
of a wide array of cellular processes necessary for normal cell growth and differentiation and its 
dysregulation is one of the hallmarks of many cancers [220]. Hence studying MYC transcriptional 
activation is critical for understanding developmental and cancer biology, as well as for the 
development of new anticancer drugs. 
Following the successful demonstration that the activity of telomerase can be inhibited by small 
molecule-induced stabilization of telomeric G-quadruplex, Hurley and co-workers reported the 
seminal discovery of a potential G quadruplex structure in the nuclease hypersensitive element III1 
(NHEIII1) of the promoter region of the MYC oncogene that controls up to 80%–90% of the 
transcriptional activity of this gene [221,222]. The authors further demonstrated that the transcriptional 
repression of MYC can be achieved by induction of putative G-quadruplex formation by a small 
molecule [223]. Evidently, MYC transcription was inhibited by the putative formation of the  
G-quadruplex structure in the promoter region, thus suppressing oncogenic expression [212]. 
Additional support for this idea came from cellular experiments in both our and other labs, whereby 
transcription of MYC and hTERT was inhibited upon addition of the G-quadruplex-interactive 
compound TMPyP4 [36] or the telomestatin derivative S2T1-6OTD [181,182]. Unlike telomeric  
G-quadruplexes, which can be formed from the single-stranded DNA template at the 3′ end of human 
telomeres, G-quadruplexes in gene promoter regions are constrained by the duplex nature of genomic 
DNA. It has been found that each of the single-stranded elements, in gene promoter double stranded 
DNA, could be a precursor to the formation of secondary DNA structures (G-quadruplexes and  
i-motifs on the G-rich and C-rich strands, respectively) reviewed in [224]. Each of the single strands 
have the ability to form isomorphic protruding structures, which are in equilibrium with the  
double-stranded B-DNA form of that region [181,222]. The protruding G-quadruplex structure and the 
I-motif formed on the opposite strand keep the two DNA strands separated and prevent the formation of the 
basal transcriptional complex. When this promoter region is in B-DNA form the transcription can be 
initiated [225]. Compounds that bind to and stabilize the G-quadruplex conformation have been shown to 
reduce MYC expression and are antitumorigenic, supporting the proposed hypothesis [182,226,227]. 
6. G-Quadruplex-Interactive Small-Molecules 
The therapeutic potential of G-quadruplexes has resulted in a rapidly increasing number of studies 
in which small-molecule ligands have been used to act as G-quadruplex stabilizers. Several hundreds 
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of small molecules that interact with G-quadruplexes have now been described in the literature [226–230], 
however cellular and in vivo data are only available for a small number of these compounds [193]. 
These compounds may be of natural origin such as cryptolepine, berberine and telomestatin or 
synthetic ones such as BSU1051, RHPS4, TMPyP4, pyridine or phenanthroline dicarboxamides, 
triazines, PIPER or bi- and trisubstituted acridines such as BRACO19. Other potential G-quadruplex-
targeting drugs including quindoline derivatives and 307A has shown various levels of selectivity and 
potency in binding to G-quadruplexes (Table 2). Many such agents are currently in various stages of 
preclinical testing and some of them will likely enter the clinic in the near future [199]. 
Table 2. Small molecules showed antitumor activity in both adults and pediatric cancers. 
Reviewed in [229,230]. 
Ligand Tumor model tested Antitumor activity Reference 
Telomestatin 
Neuroblastoma, myeloma, 
acute leukemia and glioma 
stem cells 
• Telomerase inhibition, 
telomere length reduction 
• Inhibition of proto-oncogene 
c-Myb expression 
• Antiprolifrative activity, 
apoptosis induction and 
increased chemosensitivity 
• Impairs cancer stem cell 
survival and growth 
[231–240] 
S2T1-6OTD 
(telomestatin 
synthetic Derivative) 
Paediatric brain cancer 
(Medulloblastoma and 
atypical teratoid/rhabdoid)  
• MYC and hTERT inhibition 
• Telomere shortening 
• Cell cycle arrest and tumor 
cell’s growth inhibition 
[182] 
HXDV 
(telomestatin 
synthetic 
Derivative) 
A panel of normal/cancer 
telomerase- and ALT-positive 
cell lines 
• Inhibition of cell growth 
independently of telomerase 
activity 
• M-phase cell cycle arrest 
• Mitotic defects 
• Induction of apoptosis 
[241] 
TMPyP4  
(Cationic porphyrin) 
Myeloma, cervical, 
pancreatic, breast, colon, 
prostate cancer and 
osteosarcoma, neuroblastoma 
and retinoblastoma 
• MYC and hTERT inhibition 
• Blockage of telomerase 
elongation 
• Antiproliferative activity 
 
[242–246] 
SYUIQ-5 and other 
quindoline 
derivatives 
Leukemia, Burkitt’s 
lymphoma, human epithelial 
carcinoma, nasopharyngeal 
carcinoma 
• MYC and hTERT inhibition 
• Antiproleferative activity 
cellular senescence; apoptosis 
induction  
[2,41,58,226,247,248] 
Tetrasubstituted 
napthalene diimides 
ligands 
Brest, prostate cancer , and 
lung adenocarcinoma 
• Inhibition of telomerase, 
activity 
[249] 
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Table 2. Cont. 
Ligand Tumor model tested Antitumor activity Reference 
Triazine derivatives Melanoma, mouth, lung, 
colon cancer as well as, lung 
adenocarcinoma 
• Impairs the splicing machinery 
of hTERT by stabilizing 
quadruplexes located in the 
hTERT intron 6 
• Telomere shortening 
• Antitelomerase activity, 
senescence and cancer cell 
growth arrest 
[250–254] 
Trisubstituted 
acridine (AS1410) 
Breast and lung cancer • Synergistic activity in 
combination with cisplatin 
[255] 
BRACO-19  
3,6,9-trisubstituted 
acridine 
Breast and prostate cancer, 
uterus and vulval carcinoma 
• Decreases hTERT expression 
• Induction of cellular 
senescence; cessation of cell 
growth 
[252,253,256–260] 
Pentacyclic 
acridines (RHPS4) 
Melanoma, breast and vulval 
cancer 
• Telomerase inhibition 
• Telomere capping disruption 
• Apoptosis via PARP-1 
activation 
• Cell cycle perturbations and 
decrease in cancer cell growth 
• Increased sensitivity to 
chemotherapy 
[253,259,261–266] 
4,5-di-substituted 
acridone 
Breast and lung cancer • Inhibition of telomerase activity 
• Telomere length shorting 
• Senescence induction, cancer 
cell growth inhibition 
[267] 
Anthracene 
derivatives 
Melanoma, colon cancer and 
osteogenic sarcoma 
• Telomere dysfunction 
• Senescence and cell growth 
impairment 
[268] 
Amidoanthraquinone  
derivatives 
60 different human cancer cell 
lines 
• Telomerase inhibition  
• High anti-proliferative activity 
[269] 
Perylene derivatives Melanoma, colon and breast 
carcinomas and osteosarcoma 
and colorectal carcinoma cell 
• Selectiv for telomeric  
G-quadruplex with respect to 
duplex genomic DNA. 
• Telomerase inhibition. 
[270,271] 
Macrocyclic pyridyl  
polyoxazoles 
Oral carcinoma and breast 
cancer 
• Selective for G-quadruplex 
DNA with no stabilization of 
duplex DNA or RNA 
• Cytotoxic to cancer cell line 
[272,273] 
Triethylene 
tetramine (TETA) 
Brest cancer and human 
epithelial carcinoma 
• Telomerase activity inhibition  
• Induction of cellular senescence 
[274,275] 
Bisquinolinium 
pyridine 
dicarboxamide 
compound (360A) 
Cervical cancer and colorectal 
carcinoma 
• Telomere aberrations 
• Impair mitotic cell progression 
and lead to cell death. 
[276,277] 
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Table 2. Cont. 
Ligand Tumor model tested Antitumor activity Reference 
307A  
2,6-pyridin-
dicarboxamide 
derivative 
Glioma and osteosarcoma • Equipotent against MYC and 
telomeric G-quadruplex-
forming sequences 
• Inhibiting proliferation and 
induce apoptosis 
[278] 
Bisantrene 
derivatives (An1,5) 
Melanoma and osteogenic 
sarcoma 
• Inhibit telomerase activity 
• long-term cell growth 
inhibition in both 
telomerase- and ALT-
positive cancer cell lines 
• Induction of senescence and 
autophagy 
[268] 
Two of the most studied small molecules are telomestatin for telomeric and TMPyP4 for MYC 
quadruplexes. Telomestatin is one of the most potent and selective G-quadruplex binding small 
molecules known so far. Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 
that acts by inhibiting the telomerase activity of cancer cells [232]. It induces the formation of basket-
type G-quadruplex structures in the telomeric region, impairs telomere replication and inhibits growth 
of tumor cells [233]. There is compelling evidence that telomestatin as well as the synthetic BRACO19 
and RHPS4 act not only by inhibiting the catalytic function of telomerase, but also by uncapping 
telomerase from the 3′ ends of telomeres, as reviewed in [234]. Evidence of antitumor activity in 
various xenograft models has been reported for telomestatin, adding to its widely displayed anticancer 
activity in human cancer cells including multiple myeloma, acute leukemia, NB, cells where it 
inhibited telomerase activity, reduced telomere length and caused apoptotic cell death [234–236] and 
also increased chemosensitivity in some of these malignancies. Recently telomestatin was found to 
impair glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and 
inhibition of the proto-oncogene, c-Myb [237]. However no study of telomestatin has as yet progressed 
to clinical evaluation. 
TMPyP4 (mesotetra (N-methyl-4-pyridyl) porphine) TMPyP4 is a G-quadruplex-targeting ligand 
that has been used in a large number of studies. TMPyP4 is known to bind strongly to DNA 
quadruplexes by stacking on the G-tetrads at the core of the quadruplex, resulting in telomerase 
inhibition [238]. In vitro and vivo data showed that, TMPyP4 displayed an antiproliferative effect on 
cancer cells [239] through its interaction with the G-quadruplex formed in the promoter region of MYC 
gene [223] that consequently downregulate MYC and its downstream targets [36]. However, a major 
hurdle in the development of TMPyP4 as a G-quadruplex target agent is its ability to bind to duplex 
DNA [279] and triplex DNA [280]. Thus, attempts have been made to generate second-generation 
cationic porphyrins with high selectivity for G-quadruplexes [281]. A more selective agent for the 
MYC G-quadruplex is the telomestatin derivative S2T1-6OTD, which has been shown to reduce the 
expression of MYC and TERT in childhood MB and in AT/RT tumor cells and has potent 
antiproliferative effects [181,182]. 
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G-Quadruplex-Targeting Drugs in Clinical Trials 
Quarfloxin (also known as CX-3543 or itarnafloxin), is a first-in-class G-quadruplex-interacting 
compound that has reached Phase II clinical trials for the treatment of neuroendocrine/carcinoid 
tumors. Quarfloxin is a fluoroquinolone-based antitumor agent derived from norfloxin via A-62176 
and QQ58. The latter compound has a mixed mechanism of action as a topoisomerase II poison and a 
G-quadruplex interactive compound [224,279–282]. It was shown by the Hurley laboratory, the 
developer of this small molecule, that quarfloxin is highly selective for the G-quadruplex versus 
duplex or single-stranded DNA, and it is more selective for the MYC G-quadruplex versus other  
G-quadruplexes [282]. Quarfloxin disrupts the interaction between the nucleolin protein and a  
G-quadruplex DNA structure in the ribosomal DNA (rDNA) template, a critical interaction for rRNA 
biogenesis that is overexpressed in cancer cells. Disruption of this interaction may result in the 
inhibition of ribosome synthesis and tumor cell apoptosis [283,284]. Owing to its potent in vivo 
efficacy in a broad range of tumors, quarfloxin is currently in Phase II clinical trials as a single-agent 
therapy for neuroendocrine tumors. 
In addition to being potential drug targets, DNA G-quadruplexes have also been shown to be 
potential cancer therapeutics themselves. AS1411 (Antisoma, London, UK) is a guanosine-rich  
26-base G-quadruplex-forming oligonucleotide aptamer that can inhibit the growth of malignant cells 
by inducing apoptosis. AS1411 is currently in Phase II trials for the treatment of renal cancer and acute 
myeloid leukemia. AS1411 has been shown to have cancer-selective antiproliferative activity against a 
wide range of malignant cell types [199,285]. Finally, small molecules are not the only way to target 
nucleic acid structures, a high-affinity single-chain antibody has been developed which is highly 
specific for antiparallel telomeric repeats from Stylonychia lemnae macronuclei and binds to the 
telomeric repeats in vivo, not only demonstrating the concept of antibodies as ligands, but also 
providing one of the first key pieces of evidence that these structures are present in vivo, while the 
design and synthesis of new high affinity G quadruplex ligands will provide new drug candidates and 
molecular probes [35,286]. 
7. Conclusions 
Both MB and NB belong to the most challenging oncologic diseases of childhood that often show 
poor clinical prognosis. Despite intensive multimodal therapy high-risk NB and metastatic MB 
frequently acquire therapy resistance with fatal clinical outcomes, hence the development of novel 
therapeutic approaches based on identification of specific targets seems the most promising way 
forward to a better outcome. There is good evidence to suggest that MYC oncogene expression and the 
telomere maintenance process in pediatric embryonal tumor cell populations are important in 
facilitating cell divisions required for cancer cell immortalized proliferation, thus making both of them 
attractive candidates for possible therapeutic targets. The discovery of G-quadruplex structures in 
specific, biologically important regions of the genome that are greatly required by cancer cells to 
proliferate, made them a significant drug target and ever since several compounds targeting these 
structures have been discovered and shown promising anticanceractivity. The therapeutic advantages 
of such a novel approach to anticancer drugs resides in the evidence that G-quadruplex ligands 
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selectively impair the growth of cancer cells without affecting the viability of normal  
cells [240,244,249], together with the ability of some of these compounds to exert an antitumor 
activity in different in vivo models and to induce antiproliferative effects also in ALT cells [61–63]. 
However the compounds discovered so far are moving very slowly to the clinical setting and most of 
them have not yet progressed past pre-clinical investigation [287]. To advance further more efforts 
should be directed toward better understanding of the biological functions of G-quadruplexes in vivo, 
together with additional progress on the development of small molecules with realistic drug-like 
structures, higher selectivity and decreased side effects. Although research activity on telomeric and 
oncogeneic quadruplexes in embryonal tumors is still in its infancy, it is hoped that their therapeutic 
potential will encourage more future research in this exciting new area of molecular targeted therapy 
for pediatric oncology aimed towards a successful strategy for curing childhood cancer. The promise 
and potential is high: the challenges are considerable but surmountable. 
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